BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 17998831)

  • 1. Resistin is an inflammatory marker of inflammatory bowel disease in humans.
    Konrad A; Lehrke M; Schachinger V; Seibold F; Stark R; Ochsenkühn T; Parhofer KG; Göke B; Broedl UC
    Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1070-4. PubMed ID: 17998831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease.
    Valentini L; Wirth EK; Schweizer U; Hengstermann S; Schaper L; Koernicke T; Dietz E; Norman K; Buning C; Winklhofer-Roob BM; Lochs H; Ockenga J
    Nutrition; 2009 Feb; 25(2):172-81. PubMed ID: 18849144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
    Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease.
    Straub RH; Vogl D; Gross V; Lang B; Schölmerich J; Andus T
    Am J Gastroenterol; 1998 Nov; 93(11):2197-202. PubMed ID: 9820396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
    Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
    Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease.
    Koutroubakis IE; Xidakis C; Karmiris K; Sfiridaki A; Kandidaki E; Kouroumalis EA
    Eur J Clin Invest; 2006 Feb; 36(2):127-32. PubMed ID: 16436095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus.
    Mojiminiyi OA; Abdella NA
    Scand J Clin Lab Invest; 2007; 67(2):215-25. PubMed ID: 17366001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated thrombopoietin serum levels in patients with inflammatory bowel disease.
    Kapsoritakis AN; Potamianos SP; Sfiridaki AI; Koukourakis MI; Koutroubakis IE; Roussomoustakaki MI; Manousos ON; Kouroumalis EA
    Am J Gastroenterol; 2000 Dec; 95(12):3478-81. PubMed ID: 11151880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease?
    Zissis M; Afroudakis A; Galanopoulos G; Palermos L; Boura X; Michopoulos S; Archimandritis A
    Am J Gastroenterol; 2001 Jul; 96(7):2177-83. PubMed ID: 11467650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
    Ciećko-Michalska I; Fedak D; Mach T
    Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment.
    Eivindson M; Grønbaek H; Flyvbjerg A; Frystyk J; Zimmermann-Nielsen E; Dahlerup JF
    Growth Horm IGF Res; 2007 Feb; 17(1):33-40. PubMed ID: 17126585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease.
    Katsanos KH; Tsatsoulis A; Christodoulou D; Challa A; Katsaraki A; Tsianos EV
    Growth Horm IGF Res; 2001 Dec; 11(6):364-7. PubMed ID: 11914023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
    Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
    Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
    Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
    Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: a gender-stratified, cohort analysis.
    Shen J; Ran ZH; Zhang Y; Cai Q; Yin HM; Zhou XT; Xiao SD
    Thromb Res; 2009 Feb; 123(4):604-11. PubMed ID: 18499234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission.
    Herrlinger KR; Noftz MK; Dalhoff K; Ludwig D; Stange EF; Fellermann K
    Am J Gastroenterol; 2002 Feb; 97(2):377-81. PubMed ID: 11866276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease.
    Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):789-94. PubMed ID: 17700265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.